180 related articles for article (PubMed ID: 25368680)
1. Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer.
Waugh MG
J Cancer; 2014; 5(9):790-6. PubMed ID: 25368680
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
McPhail JA; Burke JE
Adv Exp Med Biol; 2020; 1274():203-222. PubMed ID: 32894512
[TBL] [Abstract][Full Text] [Related]
3. Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Ali NA; Wu J; Hochgräfe F; Chan H; Nair R; Ye S; Zhang L; Lyons RJ; Pinese M; Lee HC; Armstrong N; Ormandy CJ; Clark SJ; Swarbrick A; Daly RJ
Breast Cancer Res; 2014 Sep; 16(5):437. PubMed ID: 25200860
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme.
Waugh MG
Mol Neurobiol; 2016 Jan; 53(1):621-630. PubMed ID: 25502460
[TBL] [Abstract][Full Text] [Related]
5. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Fry MJ
Breast Cancer Res; 2001; 3(5):304-12. PubMed ID: 11597319
[TBL] [Abstract][Full Text] [Related]
7. Functional Analysis of Promoters from Three Subtypes of the PI3K Family and Their Roles in the Regulation of Lipid Metabolism by Insulin in Yellow Catfish Pelteobagrus fulvidraco.
Zhuo MQ; Luo Z; Xu YH; Li DD; Pan YX; Wu K
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29337882
[TBL] [Abstract][Full Text] [Related]
8. A complex comprising phosphatidylinositol 4-kinase IIIβ, ACBD3, and Aichi virus proteins enhances phosphatidylinositol 4-phosphate synthesis and is critical for formation of the viral replication complex.
Ishikawa-Sasaki K; Sasaki J; Taniguchi K
J Virol; 2014 Jun; 88(12):6586-98. PubMed ID: 24672044
[TBL] [Abstract][Full Text] [Related]
9. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
Silva GO; He X; Parker JS; Gatza ML; Carey LA; Hou JP; Moulder SL; Marcom PK; Ma J; Rosen JM; Perou CM
Breast Cancer Res Treat; 2015 Jul; 152(2):347-56. PubMed ID: 26109346
[TBL] [Abstract][Full Text] [Related]
10. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
11. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.
Rizzolo P; Navazio AS; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Scarnò M; Tommasi S; Palli D; Ottini L
Oncotarget; 2016 Nov; 7(45):74097-74106. PubMed ID: 27765917
[TBL] [Abstract][Full Text] [Related]
12. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
Mesquita B; Lopes P; Rodrigues A; Pereira D; Afonso M; Leal C; Henrique R; Lind GE; Jerónimo C; Lothe RA; Teixeira MR
Breast Cancer Res Treat; 2013 Feb; 138(1):37-45. PubMed ID: 23329352
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Knobbe CB; Reifenberger G
Brain Pathol; 2003 Oct; 13(4):507-18. PubMed ID: 14655756
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of phosphatidylinositol 4-kinase IIIβ (PI4KB) - 14-3-3 protein complex reveals internal flexibility and explains 14-3-3 mediated protection from degradation in vitro.
Chalupska D; Eisenreichova A; Różycki B; Rezabkova L; Humpolickova J; Klima M; Boura E
J Struct Biol; 2017 Oct; 200(1):36-44. PubMed ID: 28864297
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
[TBL] [Abstract][Full Text] [Related]
16. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage.
Luoh SW; Venkatesan N; Tripathi R
Oncogene; 2004 Feb; 23(7):1354-63. PubMed ID: 14691457
[TBL] [Abstract][Full Text] [Related]
18. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
[TBL] [Abstract][Full Text] [Related]
20. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
